| Business Summary | | Harvard
Scientific
Corp.
is
a
development-stage
biopharmaceutical
company
with
two
lines
of
business.
The
Company
utilizes
medically
researched
and
developed
drug
substances,
determines
the
ability
of
these
substances
to
be
encapsulated
in
liposomes
and
determines
the
potential
market
for
such
products.
Through
its
acquired
group
of
entertainment
businesses,
the
Company
intends
to
conduct
and
conclude,
either
on
its
own
or
with
the
assistance
of
an
industry
partner,
all
clinical
testing
necessary
for
regulatory
approval
of
such
products
from
the
United
States
Food
and
Drug
Administration,
or
similar
regulatory
agencies
in
foreign
countries,
in
order
to
initiate
marketing
and
establish
distribution
channels
for
its
products.
During
2001,
the
Company
plans
to
devote
its
resources
to
the
entertainment
businesses. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Harvard
Scientific
Corp.
is
a
development
stage
biopharmaceutical
company
engaged
in
the
development,
commercialization,
marketing
and
distribution
of
products
utilized
in
the
treatment
of
sexual
dysfunction.
For
the
fiscal
year
ended
12/31/00,
the
Company
reported
no
revenues.
Net
loss
totaled
$399
thousand,
up
from
$57
thousand.
Higher
loss
reflects
increased
general
and
administrative
costs,
settlement
charges
and
interest
expense. | More
from
Market Guide: Significant
Developments |
| | |
| Position | Abraham Daniels, 53 | Chairman,
CEO | Daniel De Liege, 34 | Pres,
COO, Director | Eric Steinman | Exec.
VP | Hansforth Higginbotham | Treasurer |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|